ArticlePloS one2025

Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis.

Heng Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.